Dear Dr. Knapp:

Please refer to your Supplemental New Drug Application (sNDA) dated and received April 4, 2018, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Claritin (loratadine) tablets 10 mg.

This “Prior Approval” supplemental new drug application provides for modifications to the approved backer card (front and back panels) labeling for the approved 105-count (45-and 60-count bottles) and 120-count (two 60-count bottles), each for use in clamshell package configurations, and adds a 115-count (45- and 70-count bottles) backer card (front and back panels) clamshell package configuration.

We have completed our review of this application. It is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

**LABELING**

Submit final printed labeling (FPL), as soon as they are available, but no more than 30 days after they are printed. The FPL must be identical to enclosed labeling submitted April 4, 2018, backer cards (front and back panels) for the 105-count, 115-count, and 120-count size packaging and must be in the “Drug Facts” format (21 CFR 201.66), where applicable.

The FPL should be submitted electronically according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format — Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (April 2017, Revision 4).* For administrative purposes, designate this submission “**Final Printed Labeling for approved NDA 19658/S-54.**” Approval of this submission by FDA is not required before the labeling is used.
**DRUG REGISTRATION AND LISTING**

All drug establishment registration and drug listing information is to be submitted to FDA electronically, via the FDA automated system for processing structured product labeling (SPL) files (eLIST). At the time that you submit your final printed labeling (FPL), the content of labeling (Drug Facts) should be submitted in SPL format as described at [http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm](http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm). Information on submitting SPL files using eLIST may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at [http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf](http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf). In addition, representative container or carton labeling, whichever includes Drug Facts, (where differences exist only in the quantity of contents statement) should be submitted as a JPG file.

**REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Sherry Stewart, Regulatory Project Manager, at 301-796-9618.

Sincerely,

{See appended electronic signature page}

Theresa Michele, MD
Director
Division of Nonprescription Drug Products
Office of Drug Evaluation IV
Center for Drug Evaluation and Research

ENCLOSURES:
Backer cards and clamshell for the 105-, 115- and 120-count SKU
This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

THERESA M MICHELE
10/03/2018